557 related articles for article (PubMed ID: 25724524)
1. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.
Cohen DN; Lawson SK; Shaver AC; Du L; Nguyen HP; He Q; Johnson DB; Lumbang WA; Moody BR; Prescott JL; Chandra PK; Boyd AS; Zwerner JP; Robbins JB; Tyring SK; Rady PL; Chappell JD; Shyr Y; Infante JR; Sosman JA
Clin Cancer Res; 2015 Jun; 21(11):2624-34. PubMed ID: 25724524
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.
Cammareri P; Rose AM; Vincent DF; Wang J; Nagano A; Libertini S; Ridgway RA; Athineos D; Coates PJ; McHugh A; Pourreyron C; Dayal JH; Larsson J; Weidlich S; Spender LC; Sapkota GP; Purdie KJ; Proby CM; Harwood CA; Leigh IM; Clevers H; Barker N; Karlsson S; Pritchard C; Marais R; Chelala C; South AP; Sansom OJ; Inman GJ
Nat Commun; 2016 Aug; 7():12493. PubMed ID: 27558455
[TBL] [Abstract][Full Text] [Related]
3. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
4. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
[TBL] [Abstract][Full Text] [Related]
5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
6. The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.
Purdie KJ; Proby CM; Rizvi H; Griffin H; Doorbar J; Sommerlad M; Feltkamp MC; der Meijden EV; Inman GJ; South AP; Leigh IM; Harwood CA
Front Microbiol; 2018; 9():1806. PubMed ID: 30154763
[No Abstract] [Full Text] [Related]
7. High-Risk Human Papillomavirus E6/E7 mRNA Is Rarely Detected in Nonanogenital Cutaneous Squamous Cell Carcinoma: An RNA In Situ Hybridization-Based Tissue Microarray Study.
Fujimoto M; Matsuzaki I; Takahashi Y; Iwahashi Y; Warigaya K; Kojima F; Jinnin M; Murata SI
Am J Dermatopathol; 2019 Mar; 41(3):205-210. PubMed ID: 30640756
[TBL] [Abstract][Full Text] [Related]
8. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
Schrama D; Groesser L; Ugurel S; Hafner C; Pastrana DV; Buck CB; Cerroni L; Theiler A; Becker JC
JAMA Dermatol; 2014 Nov; 150(11):1180-6. PubMed ID: 24943872
[TBL] [Abstract][Full Text] [Related]
9. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.
South AP; Purdie KJ; Watt SA; Haldenby S; den Breems N; Dimon M; Arron ST; Kluk MJ; Aster JC; McHugh A; Xue DJ; Dayal JH; Robinson KS; Rizvi SH; Proby CM; Harwood CA; Leigh IM
J Invest Dermatol; 2014 Oct; 134(10):2630-2638. PubMed ID: 24662767
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Holderfield M; Lorenzana E; Weisburd B; Lomovasky L; Boussemart L; Lacroix L; Tomasic G; Favre M; Vagner S; Robert C; Ghoddusi M; Daniel D; Pryer N; McCormick F; Stuart D
Cancer Res; 2014 Apr; 74(8):2238-45. PubMed ID: 24523442
[TBL] [Abstract][Full Text] [Related]
11. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.
Falchook GS; Rady P; Hymes S; Nguyen HP; Tyring SK; Prieto VG; Hong DS; Kurzrock R
JAMA Dermatol; 2013 Mar; 149(3):322-6. PubMed ID: 23552670
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.
Loeb KR; Asgari MM; Hawes SE; Feng Q; Stern JE; Jiang M; Argenyi ZB; de Villiers EM; Kiviat NB
PLoS One; 2012; 7(4):e34422. PubMed ID: 22545084
[TBL] [Abstract][Full Text] [Related]
13. No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.
Ganzenmueller T; Hage E; Yakushko Y; Kluba J; Woltemate S; Schacht V; Schulz TF; Gutzmer R
Exp Dermatol; 2013 Nov; 22(11):725-9. PubMed ID: 24112647
[TBL] [Abstract][Full Text] [Related]
14. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F; Viros A; Milagre C; Trunzer K; Bollag G; Spleiss O; Reis-Filho JS; Kong X; Koya RC; Flaherty KT; Chapman PB; Kim MJ; Hayward R; Martin M; Yang H; Wang Q; Hilton H; Hang JS; Noe J; Lambros M; Geyer F; Dhomen N; Niculescu-Duvaz I; Zambon A; Niculescu-Duvaz D; Preece N; Robert L; Otte NJ; Mok S; Kee D; Ma Y; Zhang C; Habets G; Burton EA; Wong B; Nguyen H; Kockx M; Andries L; Lestini B; Nolop KB; Lee RJ; Joe AK; Troy JL; Gonzalez R; Hutson TE; Puzanov I; Chmielowski B; Springer CJ; McArthur GA; Sosman JA; Lo RS; Ribas A; Marais R
N Engl J Med; 2012 Jan; 366(3):207-15. PubMed ID: 22256804
[TBL] [Abstract][Full Text] [Related]
15. Association Between β-Genus Human Papillomavirus and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals-A Meta-analysis.
Chahoud J; Semaan A; Chen Y; Cao M; Rieber AG; Rady P; Tyring SK
JAMA Dermatol; 2016 Dec; 152(12):1354-1364. PubMed ID: 26720285
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
18. An Emerging Issue in Oncogenic Virology: the Role of Beta Human Papillomavirus Types in the Development of Cutaneous Squamous Cell Carcinoma.
Rollison DE; Viarisio D; Amorrortu RP; Gheit T; Tommasino M
J Virol; 2019 Apr; 93(7):. PubMed ID: 30700603
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
[TBL] [Abstract][Full Text] [Related]
20. Human beta papillomavirus DNA study in primary cutaneous squamous cell carcinomas and their corresponding metastases.
Toll A; Lloveras B; Masferrer E; Ferrándiz-Pulido C; García-Patos V; Gheit T; Pujol RM; Tommasino M
Arch Dermatol Res; 2014 Jan; 306(1):93-5. PubMed ID: 24173126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
